Announcements Trials
Browse Landscape

Phase

Phase 2 13Phase 1/2 9Phase 1 9Phase 3 5Phase NA 1Phase EARLY_PHASE1 1Phase 2/3 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 1

Interventions

Exercise 439Blood Specimen Collection 333Standard of Care 321Magnetic Resonance Spectroscopy 259Radiotherapy 255Surveys and Questionnaires 245Radiosurgery 245Educational Status 230Methods 229Early Intervention, Educational 218Practice Guidelines as Topic 146Interviews as Topic 146Biopsy 146Surgical Procedures, Operative 135Drug Therapy 133Control Groups 128Acupuncture Therapy 124Therapeutics 110Cyclophosphamide 103Palliative Care 101Counseling 101Resistance Training 95Saline Solution 90Cisplatin 90Magnetic Resonance Imaging 89Radiofrequency Ablation 86Specimen Handling 79Radiotherapy, Intensity-Modulated 79Colonoscopy 79Cognitive Behavioral Therapy 72

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × oblimersen × Clear all
NCT00070343 2014-01-06

Oblimersen and Dacarbazine in Treating Patients With Advanced Malignant Melanoma That Has Responded to Treatment on Clinical Trial GENTA-GM301

National Cancer Institute (NCI)

Phase NA Unknown
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡